These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 22212571

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W.
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [Abstract] [Full Text] [Related]

  • 24. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.
    Hézode C.
    Liver Int; 2012 Feb; 32 Suppl 1():32-8. PubMed ID: 22212569
    [Abstract] [Full Text] [Related]

  • 25. Boceprevir for chronic HCV genotype 1 infection.
    Limaye AR, Draganov PV, Cabrera R.
    N Engl J Med; 2011 Jul 14; 365(2):176; author reply 177-8. PubMed ID: 21751914
    [No Abstract] [Full Text] [Related]

  • 26. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M.
    J Infect Dis; 2013 Sep 14; 208(6):1000-7. PubMed ID: 23801602
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, ADVANCE Study Team.
    N Engl J Med; 2011 Jun 23; 364(25):2405-16. PubMed ID: 21696307
    [Abstract] [Full Text] [Related]

  • 29. Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.
    Foote BS, Spooner LM, Belliveau PP.
    Ann Pharmacother; 2011 Sep 23; 45(9):1085-93. PubMed ID: 21828346
    [Abstract] [Full Text] [Related]

  • 30. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
    Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC.
    AIDS; 2015 Jan 02; 29(1):53-8. PubMed ID: 25387314
    [Abstract] [Full Text] [Related]

  • 31. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F, CUPIC Study Group.
    Clin Res Hepatol Gastroenterol; 2015 Sep 02; 39(4):443-50. PubMed ID: 25636238
    [Abstract] [Full Text] [Related]

  • 32. [New agents for the treatment of hepatitis C].
    Buti M, Homs M.
    Enferm Infecc Microbiol Clin; 2012 Mar 02; 30(3):147-50. PubMed ID: 22118805
    [Abstract] [Full Text] [Related]

  • 33. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Ogawa E, Furusyo N, Dohmen K, Kajiwara E, Kawano A, Nomura H, Takahashi K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Viral Hepat; 2015 Dec 02; 22(12):992-1001. PubMed ID: 26075320
    [Abstract] [Full Text] [Related]

  • 34. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients.
    Burney T, Dusheiko G.
    Expert Rev Anti Infect Ther; 2011 Feb 02; 9(2):151-60. PubMed ID: 21143041
    [Abstract] [Full Text] [Related]

  • 35. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T, Hueppe D, Mauss S, Buggisch P, Pfeiffer-Vornkahl H, Grimm D, Galle PR, Alshuth U.
    J Gastrointestin Liver Dis; 2016 Mar 02; 25(1):15-24. PubMed ID: 27014750
    [Abstract] [Full Text] [Related]

  • 36. Boceprevir: a protease inhibitor for the treatment of hepatitis C.
    Chang MH, Gordon LA, Fung HB.
    Clin Ther; 2012 Oct 02; 34(10):2021-38. PubMed ID: 22975763
    [Abstract] [Full Text] [Related]

  • 37. New treatments for chronic hepatitis C virus infection.
    Corouge M, Pol S.
    Med Mal Infect; 2011 Nov 02; 41(11):579-87. PubMed ID: 21764234
    [Abstract] [Full Text] [Related]

  • 38. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.
    Clin Infect Dis; 2014 Dec 15; 59(12):1768-76. PubMed ID: 25139963
    [Abstract] [Full Text] [Related]

  • 39. What's new in HCV genotype 2 treatment.
    Mangia A, Mottola L.
    Liver Int; 2012 Feb 15; 32 Suppl 1():135-40. PubMed ID: 22212584
    [Abstract] [Full Text] [Related]

  • 40. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.
    Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P.
    Liver Int; 2010 Oct 15; 30(9):1259-69. PubMed ID: 20633102
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.